Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study | Zendy

Lorenzo Antonuzzo | Zendy; Elisa Giommoni | Zendy; Davide Pastorelli | Zendy; Tiziana Pia Latiano | Zendy; Ida Pavese | Zendy; D. Azzarello | Zendy; Michele Aieta | Zendy; Ilaria Pastina | Zendy; Francesca Di Fabio | Zendy; Alessandro Bertolini | Zendy; Domenico Corsi | Zendy; Selene Mogavero | Zendy; Valentina Angelini | Zendy; Mario Pazzagli | Zendy; Francesco Di Costanzo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study

Author(s) -

Lorenzo Antonuzzo,

Elisa Giommoni,

Davide Pastorelli,

Tiziana Pia Latiano,

Ida Pavese,

D. Azzarello,

Michele Aieta,

Ilaria Pastina,

Francesca Di Fabio,

Alessandro Bertolini,

Domenico Corsi,

Selene Mogavero,

Valentina Angelini,

Mario Pazzagli,

Francesco Di Costanzo

Publication year - 2015

Publication title -

world journal of gastroenterology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.427

H-Index - 155

eISSN - 2219-2840

pISSN - 1007-9327

DOI - 10.3748/wjg.v21.i23.7281

Subject(s) - medicine , bevacizumab , colorectal cancer , kras , adverse effect , population , clinical endpoint , progression free survival , gastroenterology , oxaliplatin , capecitabine , oncology , chemotherapy , cancer , surgery , randomized controlled trial , environmental health

To confirm the efficacy and safety of bevacizumab/XELOX combination for the treatment of locally advanced or metastatic colorectal cancer (CRC) in Italy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research